Related references
Note: Only part of the references are listed.Enhancing the Stability and Immunomodulatory Activity of Liposomal Spherical Nucleic Acids through Lipid-Tail DNA Modifications
Brian Meckes et al.
SMALL (2018)
A retrospective examination of the US Food and Drug Administration's clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
Brett Fleisher et al.
ONCOTARGETS AND THERAPY (2018)
Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel
Honglin Jin et al.
ACS NANO (2018)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Nanomaterial-Enabled Cancer Therapy
Sabina Quader et al.
MOLECULAR THERAPY (2017)
Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis
Tyler J. Goodwin et al.
VACCINE (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Relationships between Poly(ethylene glycol) Modifications on RNA-Spherical Nucleic Acid Conjugates and Cellular Uptake and Circulation Time
Alyssa B. Chinen et al.
BIOCONJUGATE CHEMISTRY (2016)
Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel
Xin Luan et al.
BIOMATERIALS (2016)
Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach
Yao Lu et al.
CANCER LETTERS (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer
Yang Xiong et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Adequately-Sized Nanocarriers Allow Sustained Targeted Drug Delivery to Neointimal Lesions in Rat Arteries
Ryosuke Taniguchi et al.
MOLECULAR PHARMACEUTICS (2016)
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
Chunbai He et al.
NATURE COMMUNICATIONS (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Synthetic Nanoparticles for Vaccines and Immunotherapy
Darrell J. Irvine et al.
CHEMICAL REVIEWS (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect
Elizabeth Huynh et al.
NANOMEDICINE (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
Clinical overview of metronomic chemotherapy in breast cancer
Elisabetta Munzone et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency
Edward A. Sykes et al.
ACS NANO (2014)
Curable Patient With Metastatic Colorectal Cancer: Balancing Effective Therapies and Toxicities
Katherine Van Loon et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy
Demin Liu et al.
NATURE COMMUNICATIONS (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
p53 and Translation Attenuation Regulate Distinct Cell Cycle Checkpoints during Endoplasmic Reticulum (ER) Stress
Sally E. Thomas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment
Julia Y. Ljubimova et al.
JOURNAL OF DRUG TARGETING (2013)
Role of inflammatory dendritic cells in innate and adaptive immunity
Cindy Hespel et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin
Ruben Hernandez-Alcoceba et al.
ONCOIMMUNOLOGY (2012)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice
Manuela Gonzalez-Aparicio et al.
GUT (2011)
The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine
Youyou Tu
NATURE MEDICINE (2011)
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Laurence Zitvogel et al.
CLINICAL CANCER RESEARCH (2010)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
Design considerations for tumour-targeted nanoparticles
Hak Soo Choi et al.
NATURE NANOTECHNOLOGY (2010)
Microsatellite instability in colorectal cancer-the stable evidence
Eduardo Vilar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Immunogenic and tolerogenic cell death
Douglas R. Green et al.
NATURE REVIEWS IMMUNOLOGY (2009)
FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer
Saima Sharif et al.
CANCER INVESTIGATION (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis
M. Obeid et al.
CELL DEATH AND DIFFERENTIATION (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Drug delivery systems: Entering the mainstream
TM Allen et al.
SCIENCE (2004)
Dendritic cells: Specialized and regulated antigen processing machines
I Mellman et al.
CELL (2001)
Share Paper
